Tumor pHe-triggered charge-reversal and redox-responsive nanoparticles for docetaxel delivery in hepatocellular carcinoma treatment
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tumor pHe-triggered charge-reversal and redox-responsive nanoparticles for docetaxel delivery in hepatocellular carcinoma treatment
Authors
Keywords
-
Journal
Nanoscale
Volume 7, Issue 38, Pages 15763-15779
Publisher
Royal Society of Chemistry (RSC)
Online
2015-08-21
DOI
10.1039/c5nr04612b
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Nucleolin targeting AS1411 aptamer modified pH-sensitive micelles for enhanced delivery and antitumor efficacy of paclitaxel
- (2015) Jinming Zhang et al. Nano Research
- Redox-responsive polyanhydride micelles for cancer therapy
- (2014) Jie Wang et al. BIOMATERIALS
- Stimuli-responsive cross-linked micelles for on-demand drug delivery against cancers
- (2013) Yuanpei Li et al. ADVANCED DRUG DELIVERY REVIEWS
- pH-Triggered Charge-Reversal Polypeptide Nanoparticles for Cisplatin Delivery: Preparation and In Vitro Evaluation
- (2013) Yue Huang et al. BIOMACROMOLECULES
- Tumor extracellular acidity-activated nanoparticles as drug delivery systems for enhanced cancer therapy
- (2013) Jin-Zhi Du et al. BIOTECHNOLOGY ADVANCES
- Redox and pH-responsive degradable micelles for dually activated intracellular anticancer drug release
- (2013) Wei Chen et al. JOURNAL OF CONTROLLED RELEASE
- Nanoparticle and targeted systems for cancer therapy
- (2012) Lisa Brannon-Peppas et al. ADVANCED DRUG DELIVERY REVIEWS
- The Effect of Nanoparticle Size, Shape, and Surface Chemistry on Biological Systems
- (2012) Alexandre Albanese et al. Annual Review of Biomedical Engineering
- pH-sensitive poly(histidine)-PEG/DSPE-PEG co-polymer micelles for cytosolic drug delivery
- (2012) Hong Wu et al. BIOMATERIALS
- Enhanced in vitro and in vivo therapeutic efficacy of codrug-loaded nanoparticles against liver cancer
- (2012) Baorui Liu et al. International Journal of Nanomedicine
- Nanomedicine in cancer therapy: Innovative trends and prospects
- (2011) Elvin Blanco et al. CANCER SCIENCE
- Glutathione-responsive nano-vehicles as a promising platform for targeted intracellular drug and gene delivery
- (2011) Ru Cheng et al. JOURNAL OF CONTROLLED RELEASE
- Anti-tumor drug delivery of pH-sensitive poly(ethylene glycol)-poly(L-histidine-)-poly(L-lactide) nanoparticles
- (2011) Rong Liu et al. JOURNAL OF CONTROLLED RELEASE
- Receptor-Mediated Endocytosis of Nanoparticles of Various Shapes
- (2011) Robert Vácha et al. NANO LETTERS
- Docetaxel loaded oleic acid-coated hydroxyapatite nanoparticles enhance the docetaxel-induced apoptosis through activation of caspase-2 in androgen independent prostate cancer cells
- (2010) Yun Luo et al. JOURNAL OF CONTROLLED RELEASE
- Effect of Nanoparticle Surface Charge at the Plasma Membrane and Beyond
- (2010) Rochelle R. Arvizo et al. NANO LETTERS
- The role of signaling pathways in the development and treatment of hepatocellular carcinoma
- (2010) S Whittaker et al. ONCOGENE
- Interaction of Nanoparticles with Cells
- (2009) Volker Mailänder et al. BIOMACROMOLECULES
- Degradable Poly(β-amino ester) nanoparticles for cancer cytoplasmic drug delivery
- (2009) Youqing Shen et al. Nanomedicine-Nanotechnology Biology and Medicine
- A Surface-Charge Study on Cellular-Uptake Behavior of F3-Peptide-Conjugated Iron Oxide Nanoparticles
- (2009) Yu Zhang et al. Small
- The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma
- (2008) Zhenghong Xu et al. BIOMATERIALS
- Nanoparticle therapeutics: an emerging treatment modality for cancer
- (2008) Mark E. Davis et al. NATURE REVIEWS DRUG DISCOVERY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More